# Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

> **NCT07631650** · PHASE2 · RECRUITING · sponsor: **Matthew Spector** · enrollment: 40 (estimated)

## Conditions studied

- Head and Neck Disorder
- Head and Neck Cancer

## Interventions

- **DRUG:** Bevonescein (ALM 488) Infusion

## Key facts

- **NCT ID:** NCT07631650
- **Lead sponsor:** Matthew Spector
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-18
- **Primary completion:** 2027-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07631650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07631650, "Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07631650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*